# Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

> **NCT02737228** · PHASE1,PHASE2 · UNKNOWN · sponsor: **CrystalGenomics, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** CG200745 PPA
- **DRUG:** Gemcitabine
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02737228
- **Lead sponsor:** CrystalGenomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02737228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02737228, "Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02737228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*